TLR9 Agonist May Reverse Resistance to Immune Checkpoint Inhibition in Melanoma
Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Melanoma SiteTerms/www.cannabissciencetech.com/News Source Type: news